natgillin/translations-raw huggingface dataset:
ml opløsning i en cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og et og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml opløsning i en cylinderampul (type 1 farveløst glas) med et stempel (chlorobutylgummi) og en skiveforsegling (laminat af polyisopren og bromobutylgummi) med en aluminiumshætte.
mL solution in a cartridge (type 1 colourless glass) with a plunger (chlorobutyl rubber) and a disc seal (laminate of polyisoprene and bromobutyl rubber) with aluminium seal.
ml opløsning i en cylinderampul (type 1, farveløst glas) med et stempel (elastomerisk bromobutyl gummi) og en ombøjet hætte (aluminium) med en prop (elastomerisk bromobutyl gummi).
ml solution in a cartridge (type I colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
ml opløsning i en cylinderampul (type 1, farveløst glas) med et stempel (elastomerisk bromobutylgummi) og en ombøjet hætte (aluminium) med en prop (elastomerisk bromobutylgummi).
ml solution in a cartridge (type I colourless glass) with a plunger (elastomeric bromobutyl rubber) and a flanged cap (aluminium) with a stopper (elastomeric bromobutyl rubber).
ml opløsning i et hætteglas (type 1) til engangsbrug med (butyl-) gummiprop og forsegling af aluminium.
ml solution in a single use Type 1 glass vial with (butyl) rubber stopper and aluminium over-seal.
ml opløsning indeholder 0,3 mg bimatoprost og 5 mg timolol (svarende til 6,8 mg timololmaleat).
One ml of solution contains 0.3 mg of bimatoprost and 5 mg of timolol (as 6.8 mg of timolol maleate).
ml opløsning indeholder 0,3 mg bimatoprost.
One ml of solution contains 0.3 mg bimatoprost.
ml opløsning indeholder 100 enheder insulin detemir (svarende til 14,2 mg).
ml solution contains 100 units insulin detemir (equivalent to 14.2 mg).
ml opløsning indeholder 30 mikrogram travoprost.
One mL of solution contains 30 micrograms of travoprost.
ml oral opløsning 150 ml oral opløsning 480 ml oral opløsning
ml oral solution 150 ml oral solution 480 ml oral solution
ml rund uigennemsigtig polyethylenflaske med lav densitet og med dråbespids og hvidt skruelåg (DROP-TAINER) af polypropylen, der indeholder 5 ml suspension.
ml round opaque low density polyethylene bottles with a dispensing plug and white polypropylene screw cap (DROP-TAINER) containing 5 ml suspension.
ml solvens
injection
ml solvens: Hætteglas af type I-glas.
ml solvent: Type I glass vial.
ml suspension en cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og en hætte (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i cylinderampul (type 1 farveløs glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)), og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1))l og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i cylinderampul af (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og en hætte (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi) (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi) (type 1)).
mlsuspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel (brombutylgummi (type 1)), ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel brombutylgummi (type 1) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi) (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi) (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1 farveløst glas) med et stempel brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi) (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type 1, farveløst glas), med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type1 farveløst glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og brombutylgummi (type 1)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul (type1 farveløst glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og brombutylgummi (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i en cylinderampul af (type 1 farveløst glas) med et stempel (brombutylgummi type 1)), ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I)).
ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
ml suspension i hætteglas (type 1 farveløst glas) med ombøjet hætte (aluminium) en prop (chlorbutylgummi (type 1)) og aftageligt låg (polypropylen).
10 ml suspension in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
ml suspension indeholder 1 g mycophenolatmofetil efter rekonstitution.
ml suspension contains 1 g mycophenolate mofetil when reconstituted.
ml vand til injektionsvæsker
ml water for injections
ml/time
ml/hour
MM/ÅÅÅÅ
{MM/YYYY}
MM/ÅÅÅÅ>
MM/YYYY
MMF: monitorering for MPA- relaterede toksicitet tilrådes.
MMF: monitoring for MPA- related toxicities is advised.
MMR ved 12 måneder
MMR at 12 months
MMR ved 12 måneder
MMRat 12 months
MMR ved 24 måneder
MMR at 24 months
MMR ved 36 måneder2
MMR at 36 months2
MMR ved 48 måneder3
MMR at 48 months3
MMR ved 60 måneder4
MMR at 60 months4
MMR ved 72 måneder5
MMR at 72 months5
MMR- rate ved 12 måneder var statistisk signifikant højere for nilotinib 300 mg 2 gange dagligt sammenlignet med imantinib 400 mg 1 gang dagligt (44,3 % vs.
The MMR rate at 12 months was statistically significantly higher for nilotinib 300 mg twice daily compared to imatinib 400 mg once daily (44.3% versus 22.3%, p<0.0001).
MMR-raten for alle Sokal-risikogrupper ved alle tidspunkter forblev konstant højere i de to nilotinib- grupper end i imatinib-gruppen.
For all Sokal risk groups, the MMR rates at all time points remained consistently higher in the two nilotinib groups than in the imatinib group.
MN
SRH MN
MN = Multipler af normal, CI = confidence interval [konfidensinterval] a Ved baseline var de gennemsnitlige miltvolumener 12,5 og 13,9 MN i henholdsvis placebo- og Cerdelga-grupperne, og de gennemsnitlige levervolumener var 1,4 MN for begge grupper.
MN = Multiples of Normal, CI = confidence interval a At baseline, mean spleen volumes were 12.5 and 13.9 MN in the placebo and Cerdelga groups, respectively, and mean liver volumes were 1.4 MN for both groups.
MN = Multipler af normal, CI = konfidensinterval
MN = Multiples of Normal, CI = confidence interval
MN- resultater viste i lighed med SRH-resultater et stærkt immunrespons efter gennemførelse af priming- vaccinationsserien hos en population af ældre forsøgspersoner.
MN results, similar to SRH results demonstrated strong immune response after completion of priming vaccination series in a population of elderly subjects.
MN-analyse
MN assay
MN-resultater for A/H5N1/Indonesia/5/05 viste en seroprotektionsrate på 38 % (31-45) hos voksne (18-60 år) og 14 % (8-20) hos ældre (>60 år); en serokonverteringsrate på 58 % (50-65) hos voksne og 30 % (23-38) hos ældre samt en GMR på 4,67 (3,95-5,56) hos voksne og 2,19 (1,86-2,58) hos ældre.
MN results for A/H5N1/Indonesia/5/05 revealed a seroprotection rate of 38% (31-45) in adults (18-60 years) and 14% (8-20) in elderly (>60 years); a seroconversion rate of 58% (50-65) in adults and 30% (23-38) in elderly and finally a GMR of 4.67 (3.95-5.56) in adults and 2.19 (1.86-2.58) in elderly.
MN-resultater for A/H5N1/Vietnam/1194/2004 viste en seroprotektionsrate på 10 % (6-16) hos voksne (18-60 år) og 6 % (3-11) hos ældre (>60 år); en serokonverteringsrate på 19 % (13-25) hos voksne og 7 % (4-13) hos ældre samt en GMR på 1,86 (1,63-2,12) hos voksne og 1,33 (1,17-1,51) hos ældre.
MN results for A/H5N1/Vietnam/1194/2004 revealed a seroprotection rate of 10% (6-16) in adults (18-60 years) and 6% (3-11) in elderly (>60 years); a seroconversion rate of 19% (13-25) in adults and 7% (4-13) in elderly and finally a GMR of 1.86 (1.63-2.12) in adults and 1.33 (1.17-1.51) in elderly.
MN-resultater for de tre kliniske studier i ovenstående tabel viste en seroprotektionsrate og en serokonverteringsrate mod A/turkey/Turkey/05 i området fra henholdsvis 10 % (2-27) til 39 % (32-46) og 10 % (2-27) til 36 % (29-43).
MN results for the three clinical studies in the Table above revealed a seroprotection rate and seroconversion rate against A/turkey/Turkey/05 ranging from 10% (2-27) to 39% (32-46) and 10% (2-27) to 36% (29-43) respectively.
MN-resultater fra de kliniske studier i ovenstående tabel afslørede en seroprotektion mod A/turkey/Turkey/05 på 27 % (17-39) (studie V87P1) til 39% (32-46) (studie V87P13) og en serokonvertering på 36 % (29-43) for studie V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 27% (17-39) (V87P1) to 39% (32-46) (V87P13) and seroconversion rate of 36% (29-43) for V87P13 study.
MN-resultater fra de kliniske studier i ovenstående tabel viste en seroprotektion mod A/turkey/Turkey/05 på 11 % (3-25) (studie V87P1) til 30 % (24-37) (studie V87P13) og en serokonvertering på 25 % (19-31) for studie V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 11% (3-25) (study V87P1) to 30% (24-37) (study V87P13) and seroconversion rate of 25% (19-31) for study V87P13.
MN-resultater fra de kliniske studier i ovenstående tabel viste en seroprotektion mod A/turkey/Turkey/05 på 27 % (17-39) (studie V87P1) til 39% (32-46) (studie V87P13) og en serokonvertering på 36 % (29-43) for studie V87P13.
MN results for the clinical studies in the Table above revealed a seroprotection rate against A/turkey/Turkey/05 ranging from 27% (17-39) (V87P1) to 39% (32-46) (V87P13) and seroconversion rate of 36% (29-43) for study V87P13.
MN-resultater fra studie V87P13 gav en GMR mod A/turkey/Turkey/05 på 2,01 (1,78-2,26).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.01 (1.78-2.26).
MN-resultater fra studie V87P13 gav en GMR mod A/turkey/Turkey/05 på 2,77 (2,4-3,2).
MN results in V87P13 yielded a GMR against A/turkey/Turkey/05 of 2.77 (2.4-3.2).
MN-resultater mod homolog A/Vietnam/1194/2004 tyder på en seroprotektions- og serokonverteringsrate i området fra henholdsvis 57 % (50-64) til 79 % (68-87) og 55 % (48-62) til 58 % (47-69).
MN results against homologous A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from of 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69) respectively.
MN-resultater mod homolog A/Vietnam/1194/2004 tyder på en seroprotektions- og serokonverteringsrate i området fra henholdsvis 67 % (60-74) til 85 % (78-90) og 65 % (58-72) til 83 % (77-89).
MN results against homologous A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively.
MN-resultater viste i lighed med SRH-resultater et stærkt immunrespons efter gennemførelse af priming-vaccinationsserien hos en population af ældre forsøgspersoner.
MN results, similar to SRH results demonstrated strong immune response after completion of priming vaccination series in a population of elderly subjects.
MN-resultaterne viste i lighed med SRH-resultaterne et stærkt immunrespons efter gennemførelse af primer-vaccinationsserier hos en population af ældre forsøgspersoner.
MN results, similar to SRH results demonstrated strong immune response after completion of priming vaccination series in a population of elderly subjects.
MN-titer ≥ 20
MN titer ≥ 20
MN-titer ≥ 20
MN titre ≥ 20
MN-titer ≥ 20 a 21 dage efter 2. dosis
MN titre ≥ 20 a 21 days after 2nd dose
MN-titer ≥20
MN titer ≥ 20
MN-titer ≥20
MN titre ≥ 20
MNS (Malignt neuroleptikas syndrom):
NMS (Neuroleptic Malignant Syndrome):
MNS omfatter nogle af eller alle følgende symptomer: svær muskelstivhed, rykvise bevægelser i muskler, arme eller ben og ømhed i musklerne.
The NMS consists of some or all of the following: severe muscle stiffness, jerking movements of muscles, arms or legs, and soreness of muscles.
MO22224 evaluerede bevacizumabs virkning og sikkerhed i kombination med paclitaxel, topotecan eller pegyleret liposomal doxorubicin hos patienter med platinresistent, recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer.
MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Mobil fase: 9 mg/ml (0,9 %) natriumchloridopløsning, fri for bakteriostatiske stoffer
Mobile phase: sodium chloride 9 mg/ml (0.9%) solution, bacteriostatic-free
Mobilisering af PBPC hos raske donorer
PBPC mobilisation in normal donors
Mobilisering af PBPC’er hos raske donorer før allogen transplantation af PBPC
For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation
Mobilisering af perifere blodprogenitorceller (PBPC)
Mobilisation of peripheral blood progenitor cells (PBPC)
Mobilisering af perifere blodprogenitorceller (PBPC’er) hos patienter i myelosuppressiv eller myeloablativ behandling efterfulgt af autolog transplantation med PBPC’er.
For the mobilisation of PBPCs in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation
Mobilisering af perifere blodstamceller
Mobilisation of PBPC
Mobilisering af perifere blodstamceller (PBPC’er).
Mobilisation of peripheral blood progenitor cells (PBPCs).
Mobiliserings- og afereseprocedurerne skal udføres i samarbejde med et onkologi-hæmatologicenter med tilstrækkelig erfaring inden for dette område, og hvor monitorering af hæmatopoietiske stamceller kan foretages korrekt.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Mobilitetsnedsættelse på injektionsstedet
Injection site anesthesia Injection site dryness Injection site movement impairment
Mobitz Type II AV-blok af 2.grad eller derover
Second degree Mobitz Type II or higher AV block
Mock-up-vacciner indeholder influenza-antigener, som er anderledes end antigenerne i de aktuelt cirkulerende influenza-vira.
Mock-up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses.
Mockup-vacciner indeholder influenza-antigener, som er forskellige fra dem, der findes i den influenzavirus, der aktuelt er i omløb.
Mock-up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses.
moclobemid, medicin mod depression
moclobemide, medicine to treat depression
moclobemid, medicin mod depression
moclobemide, medicine to treat depression,
moclobemid, medicin mod depression,
moclobemide, medicine to treat depression,
moclobemid, medicin mod depression.
moclobemide, medicine to treat depression,
moclobemid, medicin mod depression.
moclobemide, medicine to treat depression.
moclobemid, mod depression.
moclobemide, medicine to treat depression,
moclobemide, een geneesmiddel om een depressie te behandelen,
moclobemide, medicine to treat depression,
mod allergisymptomer – fås i håndkøb
for allergy symptoms.
mod angst og depression
for anxiety and depression
mod angst og mild depression (naturlægemiddel) – fås i håndkøb
a herbal medicine for anxiety and mild depression.
mod angst og søvnbesvær
for anxiety or trouble sleeping
mod angst, panikanfald og søvnbesvær
for anxiety, panic attacks and trouble sleeping
Mod ankyloserende spondylitis blev Simponi sammenlignet med placebo over en periode på 24 uger i én hovedundersøgelse, som omfattede 356 patienter, der ikke havde responderet tilstrækkeligt på andre behandlinger.
For ankylosing spondylitis, Simponi was compared with placebo over 24 weeks in one main study involving 356 patients who had not responded adequately to other treatments.
mod astma
for asthma
Mod astmaanfald bør patienten bruge en separat inhalator som anfaldsmedicin til at dæmpe symptomerne.
For asthma reliever therapy, patients should take a separate ‘reliever inhaler’ to relieve their symptoms.
mod bakterie-infektion
for bacterial infections
mod bakterieinfektioner
for bacterial infections
mod blodpropper
stops blood from clotting
mod calicivirus infektion for at reducere kliniske tegn og virusudskillelse mod Chlamydophila felis infektion for at reducere kliniske tegn
against calicivirus infection to reduce clinical signs and excretion, against Chlamydophila felis infection to reduce clinical signs.
mod calicivirus infektion for at reducere kliniske tegn,
against calicivirus infection to reduce clinical signs,
mod calicivirus infektion for at reducere kliniske tegn, mod Chlamydophila felis infektion for at reducere kliniske tegn,
against calicivirus infection to reduce clinical signs, against Chlamydophila felis infection to reduce clinical signs,
mod calicivirus infektion for at reducere kliniske tegn, mod Chlamydophila felis infektion for at reducere kliniske tegn, mod felin panleukopeni til forebyggelse af dødsfald og kliniske tegn.
against calicivirus infection to reduce clinical signs, against Chlamydophila felis infection to reduce clinical signs, against feline panleucopenia to prevent mortality and clinical signs.
mod calicivirus infektion for at reducere kliniske tegn, mod felin panleukopeni til forebyggelse af dødsfald og kliniske tegn.
against calicivirus infection to reduce clinical signs, against feline panleucopenia to prevent mortality and clinical signs.
Mod colitis ulcerosa blev Simponi sammenlignet med placebo i to hovedundersøgelser hos patienter, der ikke havde responderet på eller ikke kunne få andre behandlinger.
For ulcerative colitis, Simponi was compared with placebo in two main studies in patients who had not responded to or could not use other treatments.
Mod depression og diabetiske neuropatiske smerter
For depression and diabetic neuropathic pain:
mod epilepsi
for epilepsy
mod felin panleukopeni til forebyggelse af dødsfald og kliniske tegn, mod leukæmi til forebyggelse af persistent viræmi og kliniske tegn på sygdommen.
against feline panleucopenia to prevent mortality and clinical signs, against leukaemia to prevent persistent viraemia and clinical signs of the related disease.
mod felin viral rhinotracheitis for at reducere kliniske tegn
against feline viral rhinotracheitis to reduce clinical signs,
mod felin viral rhinotracheitis for at reducere kliniske tegn,
against feline viral rhinotracheitis to reduce clinical signs,